Product
TAK-202
Aliases
MLN1202, plozalizumab
1 clinical trial
1 indication
Indication
MelanomaClinical trial
An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Patients With Advanced MelanomaStatus: Terminated, Estimated PCD: 2018-05-11